ReviewCritical reviews in oncology/hematology2017
Overcoming obstacles in the design of cancer anorexia/weight loss trials.
Review in Critical reviews in oncology/hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- The Effect of Peppermint (Integrative cancer therapiesTrial
- Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.Journal of cachexia, sarcopenia and muscle · 2024Article
- A comprehensive review of animal models for cancer cachexia: Implications for translational research.Genes & diseases · 2024Review
- Effect and Mechanism of Herbal Medicines on Cisplatin-Induced Anorexia.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Physiologic and molecular characterization of a novel murine model of metastatic head and neck cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2021Article
- A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment inOncotarget · 2021Article
- Phosphorylation of Dynamin-Related Protein 1 (DRP1) Regulates Mitochondrial Dynamics and Skeletal Muscle Wasting in Cancer Cachexia.Frontiers in cell and developmental biology · 2021Article
- Development and progression of cancer cachexia: Perspectives from bench to bedside.Sports medicine and health science · 2020Article
- Metastasis and cachexia: alongside in clinics, but not so in animal models.Journal of cachexia, sarcopenia and muscle · 2019Review
- Remarks on the design and analyses of longitudinal studies for cancer patients with anorexia and weight loss.Journal of cachexia, sarcopenia and muscle · 2019Review
- Need and demand for nutritional counselling and their association with quality of life, nutritional status and eating-related distress among patients with cancer receiving outpatient chemotherapy: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Modeling Human Cancer-induced Cachexia.Cell reports · 2019Article
- Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients.Journal of palliative medicine · 2018Article
- Cancer-associated weight loss: releasing its firm grip on negative clinical outcomes.Current opinion in supportive and palliative care · 2017Article
- The wasting-associated metabolite succinate disrupts myogenesis and impairs skeletal muscle regeneration.JCSM rapid communicationsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Most advanced cancer patients suffer loss of appetite (anorexia) and loss of weight. Despite the fact that cancer anorexia and weight loss are associated with a poor prognosis and detract from quality of life, no interventions have been demonstrated to palliate this syndrome in its entirety, particularly in patients with treatment-refractory malignancies. Recently, two registration trials - one with anamorelin and another with enobosarm - failed to reach their primary endpoints, thus raising questions. Were both these agents ineffective? Alternatively, did study design issues compromise the ability of these trials to identify effective agents? Thus, this review is timely insofar it serves as an introduction to study design, offers guidance on how to test promising agents for cancer anorexia/weight loss, and provides advice for overcoming trial design obstacles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.